QPPV.COM KNOWLEDGE ASSESSMENT

Avacopan: Drug-Induced Liver Injury and Vanishing Bile Duct Syndrome

Test your understanding of the concepts covered by Avacopan: Drug-Induced Liver Injury and Vanishing Bile Duct Syndrome.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best characterises the UK position as of 3 October 2026?

The UK authorisation had already been revoked, with no transition for existing patients. Use, sale and supply were suspended for new patients, while existing patients could receive supply during a managed transition and revocation was intended for a later date. The UK had taken no action because the EU authorisation remained in force. The UK had adopted FDA’s pending hearing process without restrictions on new patients.

Question 2 of 10 Following retraction of the 2021 ADVOCATE publication over concerns about trial conduct and altered outcome data, how should its original efficacy estimates be used?

They remain reliable because the study was once published in a peer-reviewed journal. They should be presented as historical reported results, not as reliable current evidence of efficacy. They establish that avacopan has no clinical effect in any patient. They should be treated as evidence about the cause of the liver injuries.

Question 3 of 10 Which information set would most strengthen assessment of a suspected avacopan-related liver injury?

A dated exposure and symptom timeline, serial liver tests with reference ranges, concomitant medicines, alternative-cause evaluation, management and outcome. Only the maximum ALT value and the reporter’s conclusion about causality. The patient’s age and the total number of reports in the sponsor database. A statement that the patient improved after stopping treatment, without dates or follow-up results.

Question 4 of 10 What can reasonably be inferred from the reported median time to onset of 46 days in the DILI cases?

DILI cannot occur after the first two months of treatment. Every patient should be considered free of risk after day 46. The signal includes relatively early-onset cases, but the reported range shows that individual onset times vary. The median establishes that the injury is dose-independent.

Question 5 of 10 A European patient is stopping avacopan after more than three months of treatment. Which monitoring advice described in the article applies specifically to this cessation context?

Monitor at least every two weeks until three months from treatment start. No further liver monitoring is needed once treatment has stopped. Monitor every four weeks up to six months from treatment start, then as needed. Apply the US label’s Japanese-descent schedule because it is a global standard.

Question 6 of 10 Which conclusion is justified by the fact that six of the seven reported VBDS cases came from Japan and one from Canada?

The case distribution proves a population-specific susceptibility among Japanese patients. The reports establish that VBDS occurs only in those two countries. The distribution is descriptive and, by itself, does not establish population-specific susceptibility. The geographic pattern proves that the cases were caused by a local environmental exposure.

Question 7 of 10 How should the 2026 concerns about ADVOCATE data integrity be related to the avacopan liver-safety signal?

They are the same finding, because unreliable efficacy data prove that reported DILI was caused by avacopan. The trial-data concerns invalidate all post-marketing safety reports. The liver signal resolves the question of whether the pivotal trial data were reliable. They are separate evidence issues that should be assessed independently and then considered together in the integrated benefit–risk assessment.

Question 8 of 10 A pharmacovigilance scientist is asked to estimate the incidence of avacopan-associated DILI from the 76 reported cases. What is the most appropriate response?

Do not derive incidence from this case series; it lacks an appropriate treated-population denominator and is subject to reporting limitations. Calculate incidence by dividing 76 by the number of cases with laboratory data. Use the 76 cases as the denominator and the eight deaths as the numerator. Estimate incidence from the median time to onset.

Question 9 of 10 A safety reviewer is summarising FDA’s review of 76 DILI cases, including seven cases of biopsy-confirmed VBDS. Which statement is methodologically appropriate?

There were 83 DILI cases because the VBDS cases should be added to the total. The 76 reports establish the incidence of DILI among treated patients. The 76 cases establish that every patient exposed to avacopan has the same absolute risk. The seven VBDS cases are a subset of the 76 DILI cases, and the reports do not provide an incidence estimate.

Question 10 of 10 At initial presentation, a patient has ALT at four times ULN and ALP at one times ULN. Using the article’s R-ratio approach, how should the biochemical pattern be classified?

Hepatocellular, because the R ratio is at least 5. Cholestatic, because the ALP is not elevated. Unclassifiable, because bilirubin is needed to calculate the R ratio. Mixed, because the R ratio is 4.

Avacopan: Drug-Induced Liver Injury and Vanishing Bile Duct Syndrome

Cookie Settings